361 GLOBAL LONG/SHORT EQUITY FUND INVESTOR CLASS (AGAQX US) stock market data APIs
10.8039
0(0%)
as of April 14, 2025
361 GLOBAL LONG/SHORT EQUITY FUND INVESTOR CLASS Financial Data Overview
Prev. Close
10.8039
Open
10.8039
High
10.8039
Low
10.8039
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get 361 GLOBAL LONG/SHORT EQUITY FUND INVESTOR CLASS data using free add-ons & libraries
End-of-day & Earnings data
Get 361 GLOBAL LONG/SHORT EQUITY FUND INVESTOR CLASS Earnings data
$
19.99
/mo.
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
Get 361 GLOBAL LONG/SHORT EQUITY FUND INVESTOR CLASS End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
361 GLOBAL LONG/SHORT EQUITY FUND INVESTOR CLASS News
New
Lee’s Pharmaceutical Announces its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Clearance to Start Phase 3 Trial as a First-line Treatment of Extensive-stage Small-Cell Lung Cancer
Socazolimab is an anti-PD-L1 antibody licensed from Sorrento for the Greater China Territory by Lee’s Pharm. China’s National Medical Products Administration (“NMPA”) clears Lee’s Pharm to ...
Lee’s Pharmaceutical Announces its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Clearance to Start Phase 3 Trial as a First-line Treatment of Extensive-stage Small-Cell Lung Cancer
Socazolimab is an anti-PD-L1 antibody licensed from Sorrento for the Greater China Territory by Lee’s Pharm. China’s National Medical Products Administration (“NMPA”) clears Lee’s Pharm to ...
Dr. Henry Ji to Participate in the H.C. Wainwright Virtual GLOBAL LIFE SCIENCES CONFERENCE 2021 Investor Conference
SAN DIEGO, March 04, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming co...
Sorrento Stock Is a Buy Because of Its Strong Drug Pipeline, Says Analyst
Sorrento (SRNE) has a multi-pronged approach to therapeutics. The company has been constantly adding new options to its bulging pipeline and has made two notable additions over the past month. Earlie...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
